Table 3.
Common treatment-related TEAEs (Safety set)
| MIL60 (n=256) |
Bevacizumab (n=259) |
|||
|---|---|---|---|---|
| All grade | Grade 3-5 | All grade | Grade 3-5 | |
| Neutropenia | 65 (25.4%) | 44 (17.2%) | 57 (22.0%) | 42 (16.2%) |
| Leucopenia | 63 (24.6%) | 27 (10.5%) | 65 (25.1%) | 27 (10.4%) |
| Anaemia | 57 (22.3%) | 0 | 59 (22.8%) | 0 |
| Proteinuria | 50 (19.5%) | 0 | 37 (14.3%) | 0 |
| Thrombocytopenia | 45 (17.6%) | 0 | 34 (13.1%) | 0 |
| Fatigue | 34 (13.3%) | 0 | 33 (12.7%) | 0 |
| Hypertension | 31 (12.1%) | 15 (5.9%) | 31 (12.0%) | 11 (4.2%) |
| Nausea | 25 (9.8%) | 0 | 24 (9.3%) | 0 |
| Decreased appetite | 21 (8.2%) | 0 | 23 (8.9%) | 0 |
| Epistaxis | 17 (6.6%) | 0 | 20 (7.7%) | 0 |
| Lymphocytopenia | 15 (5.9%) | 0 | 13 (5.0%) | 0 |
| Abnormal liver function | 14 (5.5%) | 0 | 10 (3.9%) | 0 |
| Diarrhoea | 12 (4.7%) | 0 | 19 (7.3%) | 0 |
| Hematuria | 12 (4.7%) | 0 | 16 (6.2%) | 0 |
| Vomiting | 11 (4.3%) | 0 | 19 (7.3%) | 0 |
| Febrile neutropenia | 8 (3.1%) | 8 (3.1%) | 13 (5.0%) | 13 (5.0%) |
Data are n (%).The table shows all treatment-related adverse events that occurred in 5% or more of patients.